Patrick E Sewell, Founder and Chief Science Officer at Triple Helix Science, highlights the powerful reality that preventative medicine is revealing; but first we must remove the brakes of entrenched healthcare systems and their stifling economics.

The science of preventative medicine is advancing rapidly, as discoveries compound and new cell and gene therapies proliferate. Conditions from Alzheimer’s to bad cholesterol now have potential preventative gene therapy treatments in various stages of testing and development. But proactive healthcare is encountering its biggest obstacle: the reactive economic model that currently dominates the healthcare industry, and will not be quick to adapt.
The science is advancing rapidly
Preventative medicine has been around for decades, aiming to pre-empt the need for future medical treatment by administering an intervention before a disease can worsen or even develop in the first place. Now, the science has accelerated to a breathtaking pace.
The newest discoveries are revolutionary, reducing risk factors or eliminating the genetic conditions in which diseases develop altogether – in some cases long before symptoms appear. Advancements in CRISPR gene editing, including the discovery of a smaller enzyme that is well placed for precision delivery, are driving the field forwards. Artificial intelligence (AI) research from Anthropic has now demonstrated the potential to discover entirely new vectors for gene therapy, beyond CRISPR treatments. Its model, Claude, recently found a new enzyme for gene editing. Reminiscent of CRISPR, it could in theory offer another pathway to apply preventative gene therapy.
This pace of development means scientists are also continuing to identify new, life-improving treatments including gene therapies that dramatically reduce bad cholesterol, and others that could potentially prevent Alzheimer’s. We’re seeing scientists explore more frequently what other age-related chronic diseases can be detected and prevented before patients experience a single symptom. These breakthroughs place us firmly in the early stages of a golden age for innovation, with developments showing no sign of slowing – in fact their potential is continuing to grow.
The economic blocker
Clearly this category of medicine can bring massive cost reductions over a lifetime of care while offering patients better quality of life. There is, however, a blocker on its implementation: the economics of healthcare systems.
The biggest, most dominant healthcare industries across the US and Europe are built around the reactive treatment of disease. According to the Centers for Disease Control and Prevention (CDC), an estimated 90 percent of the $5.3 trillion annual health expenditures in the US went towards chronic and mental health conditions in 2024. In the EU, chronic disease treatment also accounts for the lion’s share of healthcare expenditures, between 70 and 80 percent.
The prevailing economic model is therefore oriented overwhelmingly around the extraction of revenue from patients with chronic disease across a lifetime of treatment. Preventative medicine, for obvious reasons, threatens that model. In the same way kidney transplants represent a large upfront cost for patients, but dialysis costs thousands more over time, major healthcare systems tend to be biased towards the longer-term treatments that in many cases cost a lot more than one-and-done solutions.
This bias towards reactive healthcare is a massive liability for healthcare systems at large, despite being heavily incentivised. In the US, for example, costs for long-term treatments like dialysis can be allocated to insurance and public payers like Medicare, generating consistent, reliable revenue for providers as costs balloon. In fact, roughly 85 percent of US dialysis patients have public Medicare coverage.
The cost savings of a preventive approach
On a national, governmental level, it doesn’t necessarily make sense to keep pursuing the current model – especially when one-time genetic treatments can already replace the need for a lifetime of care. Take sickle cell disease, for example; a single stem cell therapy can now effectively cure it, ending the need for regular blood transfusions across the course of a patient’s life. That means major cost savings over a lifetime, and more blood available for other patients.
Another example is a treatment that allows a type 1 diabetes patient to create their own insulin at regular levels for the first time in their life – and at a far lower lifetime price point, given insulin prices are still often above the $35 price cap set out in the US’s Inflation Reduction Act.
Preventative treatments for Alzheimer’s are yet another example. It costs the average American more than $400,000 over the course of the disease, and $409 billion annually across the US economy.
But just this year, researchers at UCL in London announced the discovery of a single gene closely linked to the disease’s development, opening the door to new genetic treatments already in research. They have so far yielded promising results. Researchers from elsewhere in the UK successfully converted the APOE4 gene, closely tied to Alzheimer’s risk, to the APOE3 gene, which carries substantially less risk. That means a single genetic treatment could help prevent Alzheimer’s from ever developing, at a far lower cost than if the disease developed and had to be managed – and all without any damage to quality of life.
Bespoke genetic treatments can remove the need for a lifetime of treatment, improve individuals’ health spans and work out far cheaper over the long term. Yet clearly they are fundamentally at odds with the current incentives built into major healthcare models around the world.
Within the current environment, that poses real risks to the development of this form of medicine. First, we could lose genuinely life-altering preventative solutions because the commercial incentives aren’t in place to further drive advancements in the field. Second, these medicines could be developed but then priced at a similar level to that of lifetime treatment, pushing patients away. If either of those outcomes were to be realised, we would miss out on the massive gains this form of healthcare could deliver.
The fix
What’s the solution, then? I would argue we need to fundamentally change mindsets and priorities across the most established health systems in the world and rewire their commercial incentives. The economic models need to shift – and fast.
That starts with encouraging innovation, committing more resources to research and development, and asking different questions of our pharmaceutical industry. Eventually, we must arrive at a point where, across every disease we know about, the first question we ask is how to enter the timeline earlier. Once achieved, we’ll have reoriented entire health systems to take a different, more proactive and immediate approach to healthcare.
It’s also true that not every country is up against the same large, established healthcare industries that we see across North America and Europe. In fact, countries like those across the Global South may have the best chance of early adoption. With less entrenched healthcare industries, they have a strategic advantage here.
These nations can advance and adopt breakthroughs in preventative medicine without having to wait for a massive industry to adapt; in that way, they are the ideal places for this form of healthcare to gain momentum. Many countries across the Global South have well-developed gene research ecosystems in their own right – owing to a need for agricultural gene editing – so training for practitioners is also well within reach. With a push from national governments and greater resources, they could easily lead in preventative medicine – and push the global momentum in the right direction in the process.
In conclusion
We’re seeing positive signals; funding, for example, is catching up with the science, and private investors are now showing a real appetite for preventative medicine. Billions are being invested in this new frontier, with longevity-focused biotech companies raising approximately $3.74 billion in the first quarter of this year alone. Markets recognise this new science’s potential, alongside preventative gene therapies’ ability to generate returns. What we need now is the economic systems to match.
If we are to make the most of recent scientific progress on a truly global scale, health agencies and regulators will need to proactively create the space for these treatments, and governments will have to shift the commercial incentives that are currently so strongly geared towards reactive healthcare. It might mean gradually shifting training funds in universities, or funnelling more resources into other preventative methods, including genomic screening. Whatever the form, it must set the industry up for a generational transition – from reactive to preventative.
This kind of healthcare model offers vast cost savings and improvements to quality of life. And if we can get the final component – the economics of the industry – to the right place, it could be nothing short of revolutionary.
Patrick E Sewell, MD, is Founder and Chief Science Officer at Triple Helix Science – a biotechnology firm advancing preventative gene therapy, cell therapy, intervention medicine and other advanced therapeutic programmes. Patrick has more than 30 years of experience in interventional radiology and interventional oncology – a field he founded in 1998 – and he performed the first image-guided tumour ablations. He has published more than 100 scientific manuscripts and six books, including 2026’s Anti-Cancer Gene Therapy.



No comments yet